Bangladesh healthcare market: size, growth and outlook 2026–2032

High out-of-pocket spend and outbound patient flows to India — a core Consulting Wallah market. Published estimates normalised to 2025 range from USD 14.0 bn to USD 14.0 bn; the Consulting Wallah central estimate is USD 14.0 bn, growing at about 10% a year to USD 27.3 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by rising NCD burden (diabetes, cardiac, cancer) and ageing population; private sector delivering 70-80% of care with ~6,000 hospitals/clinics and 12,000 diagnostic centres; growing middle class and demand for tertiary/super-specialty care (Evercare 470-bed Chattogram, Labaid Cancer).

Context that matters for buyers and suppliers: Healthcare market ~USD 14 bn (2025), projected ~USD 23 bn by 2033 (hospitals, diagnostics, devices, pharma). Out-of-pocket spending ~73-74% of total health expenditure; insurance covers 2.5% of population. Bangladeshis spend USD 4-5 bn a year on treatment abroad; ~482,000 treated in India in 2024; 52% of Indian medical visas go to Bangladeshis. 171,635 hospital beds (private 99,975; government 71,660) - about one bed per 990 people.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 14.0 bn–USD 14.0 bn; differences are mostly scope.

Included: public and private hospital, clinic, diagnostic and long-term care services and the associated health expenditure. Excluded: pharmaceutical and device product sales, insurance premiums and health IT (covered in separate reports). Published totals differ mainly by whether products and insurance are folded in.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Healthcare market ~USD 14 bn (2025), projected ~USD 23 bn by 2033 (hospitals, diagnostics, devices, pharma) (The Daily Star (DCCI seminar))
• Out-of-pocket spending ~73-74% of total health expenditure; insurance covers 2.5% of population (UNB / Daily Star)
• Bangladeshis spend USD 4-5 bn a year on treatment abroad; ~482,000 treated in India in 2024; 52% of Indian medical visas go to Bangladeshis (UNB / Daily Star)
• 171,635 hospital beds (private 99,975; government 71,660) - about one bed per 990 people (TBS News (Health Minister, Feb 2024))
• Private sector: ~64% of health expenditure, ~6,000 hospitals/clinics, ~12,000 diagnostic centres, 70-80% of care delivered (US ITA)
• Pharma market ~USD 6 bn; ~98% of demand met locally; 200+ companies; top 10 hold ~two-thirds; exports ~USD 200 m to ~150 countries (US ITA)
• Medical device market projected USD 820 m in 2025, up from USD 442 m in 2020 (13% CAGR) (BIDA via Danish Trade Council)
• Evercare Hospital Chattogram is a 470-bed multi-disciplinary tertiary hospital (Evercare)
• Nearly 49% of population lacks access to quality healthcare; ~80% of hospitals lack advanced diagnostics (UNB (DCCI seminar))

Where the GCC and India sit

• Total hospital beds: 171,635 (govt 71,660; private 99,975) (2022/2024) — TBS News (Health Minister)
• Private clinics/hospitals and diagnostic centres: ~6,000 clinics/hospitals; ~12,000 diagnostic centres (2026) — US ITA Country Commercial Guide
• Private sector share of total health expenditure: ~64% (2026) — US ITA
• Bangladeshi patients treated in India: ~482,000 (2024) — UNB (DCCI seminar)
• Annual outbound medical spend: USD ~4-5 bn (2024-2025) — Daily Star / UNB
• Pharma exports: ~USD 200 m to ~150 countries (2026) — US ITA

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: repatriating part of USD 4-5 bn annual outbound spend via internationally accredited tertiary hospitals; health insurance development (2.5% coverage today); diagnostics and imaging upgrade across private facilities.

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Operators and investors: capacity, payer rules and licensing timelines decide returns; design central procurement and insurer contracting into the operating model before opening.
• Suppliers: registration, a local partner and payer-formulary presence are the gates; central tenders reward structured quotations and reliable supply over the lowest price.
• Hospital leaders: payer pressure makes the 25–35% of cost in supplies the margin lever — see the free executive assessment.

1. The Daily Star, Bangladesh's healthcare market projected to reach $23 billion by 2033 — thedailystar.net
2. UNB, USD 5 billion spent abroad annually due to healthcare gaps in Bangladesh: DCCI — unb.com.bd
3. US International Trade Administration, Bangladesh - Healthcare and Pharmaceuticals (Country Commercial Guide) — trade.gov
4. The Business Standard, Bangladesh has one hospital bed for every 990 patients: Health minister — tbsnews.net
5. Trade Council of Denmark, Health sector - Bangladesh — um.dk
6. BRAC EPL Investments, Square Pharmaceuticals equity note (FY2025) — bracepl.com
7. The Daily Star, Bangladeshis spend $4b annually for healthcare abroad — thedailystar.net
8. Evercare, Evercare Hospital Chattogram - About us — evercarebd.com
9. United Hospital / DCCI seminar (reported by The Daily Star) (2025-12) — USD 14 bn (2025) to USD 23 bn (2033), CAGR —; scope: country; hospitals + diagnostics + devices + pharma; cited from studies by United Hospital MD/CEO; UNB version gives '2030-2033' — source
10. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
11. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.